

Oncology Today with Dr Neil Love: Key Presentations on Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2020 ASH Annual Meeting — Issue 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The VIALE-A trial evaluating azacitidine in combination with either venetoclax or placebo for patients with previously untreated acute myeloid leukemia (AML) not eligible for intensive chemotherapy demonstrated which clinical outcome on the azacitidine/venetoclax arm?

 - a. Improvement in overall survival
 - b. No improvement in overall survival
2. Which of the following proteins is the target of the novel antibody magrolimab, being investigated for the treatment of AML?

 - a. CD47
 - b. PD-1
 - c. PD-L1
3. Which of the following drug types best describes the mechanism of action of the novel agent pevonedistat, being investigated for the treatment of high-risk myelodysplastic syndromes?

 - a. Immune checkpoint inhibitor
 - b. Bcl-2 inhibitor
 - c. NEDD8-activating enzyme inhibitor
4. Which of the following outcomes was reported from the QUAZAR AML-001 trial evaluating maintenance CC-486 versus placebo for patients with AML in first remission after intensive chemotherapy?

 - a. Improvement in the primary endpoint of overall survival with CC-486
 - b. No improvement in relapse-free survival with CC-486